DOMA Perpetual Issues & Mails Letter to Shareholders of Pacira BioSciences

Published: 2026-05-13 12:50:30 ET PCRX

Published on 05/13/2026 at 12:50 pm EDT

On May 13, 2026, DOMA Perpetual Capital Management sent a letter to Pacira BioSciences, Inc.?s stockholders outlining the rationale for urgently needed change in the composition of the Company's Board of Directors and emphasizing how its independent, experienced and highly qualified nominees would bring genuine independence to the Company's Board and support the much-needed maximization of stockholder value. In addition, DOMA believes the board and management are committing gross negligence by misleading investors about the true risks the business faces, compensation structure allegedly rewards executives despite poor results, and DOMA Perpetual asserts Management and the Board continue to promote a risky strategy of bet the farm litigation that has already likely cost the Company, and it argues this strategy could jeopardize the company?s future. Further, DOMA urged the shareholders of the Company to vote for its board nominees Eric de Armas, Christopher Dennis and Oliver Benton "Ben" Curtis III, at the annual meeting scheduled to be held on June 9, 2026.